Targeted drug vs chemotherapy for EGFR-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new targeted drug called SYS6010 against standard chemotherapy for people with advanced HER2-negative, EGFR-positive breast cancer. It aims to see if the new drug works better and is safe, and you will be randomly assigned to one of the two treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your breast cancer is HER2-negative and EGFR-positive.
- You have had 1 to 2 lines of chemotherapy for advanced or metastatic breast cancer.
- You have at least one tumor that can be measured on a CT or MRI scan (skin-only tumors are not enough).
- Your cancer has not spread to the brain in an uncontrolled way, and any brain lesions are stable (no symptoms and no steroids for at least 2 weeks).
- You have not previously been treated with topoisomerase I inhibitors or EGFR-targeted antibodies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination (SYS6010 and possibly SYH2051) compared to standard chemotherapy for advanced breast cancer and other solid tumors. It aims to see if this experimental treatment can shrink tumors and help people with EGFR-positive cancers, potentially offering a new option.
This trial tests a new medicine called ESG401 for people with a common type of breast cancer (HR+/HER2-) that has spread and hasn't responded to at least one chemotherapy. The goal is to see if it works better than standard chemotherapy options.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
This trial tests a new drug combination (SYS6023) for advanced breast cancer that has spread or cannot be surgically removed. The treatment targets a protein called HER3, which may help stop cancer growth in patients whose cancer has progressed despite previous treatments.
This trial tests a new approach to chemotherapy that adapts over time for people with advanced breast cancer that has not responded to first-line treatment. It is designed to personalize treatment based on how the cancer responds, potentially improving outcomes with fewer side effects.
This trial compares a new drug called SYS6010 to a standard chemotherapy drug (docetaxel) for people with advanced non-small cell lung cancer that has not responded to previous treatments. The goal is to see if the new drug works better or has fewer side effects.
Hear when a new Recurrent or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.